Loading...
OTCM
RNUGF
Nov 18, Last price  
0.00
Name

ReNeuron Group PLC

Chart & performance

D1W1MN
OTCM:RNUGF chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
11.94%
Rev. 5Y
65.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
530k
+31.51%
1,0003,0009,00049,00027,00093,00031,00029,00040,00017,00022,00030,00029,00046,00043,00049,0006,065,000257,000403,000530,000
Net income
-5m
L-44.18%
-813,000-3,214,000-6,369,000-5,249,000-6,572,000-3,667,000-5,850,000-6,148,000-6,229,000-6,345,000-7,066,000-8,906,000-11,354,000-15,573,000-17,615,000-14,292,000-11,412,000-11,347,000-9,689,000-5,408,000
CFO
-7m
L+0.99%
-2,790,000-2,786,000-4,666,000-5,529,000-6,079,000-4,401,000-2,629,000-5,148,000-5,786,000-6,022,000-6,004,000-8,245,000-11,920,000-12,636,000-14,887,000-11,992,000-14,304,000-6,052,000-7,411,000-7,484,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.

Key people

John Berriman
Non-Executive Independent Chairman of the Board · since 2018
Olav Hellebo
Chief Executive Officer, Director · since 2014
Sharon Grimster
Vice President Development and General Manager - Wales · since 2015
Nicholas Adams
Vice President - Business Development and Alliance Management · since 2019
Michael Elliott Hunt
Chief Financial Officer, Executive Director, Company Secretary · since 2015
Richard L. Beckman
Chief Medical Officer · since 2018
Randolph Corteling
Head of Research · since 2015
Mark Docherty
Non-Executive Director · since 2003
Chris Evans
Non-Executive Director · since 2013
URL
https://www.reneuron.com/
IPO date
Aug 12, 2005
Employees
26
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
C/O CORK GULLY LLP
40 VILLIERS STREET
LONDON, LND WC2N 6NJ
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT